8cau: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
The | ==human alpha7 nicotinic receptor in complex with the C4 nanobody and nicotine== | ||
<StructureSection load='8cau' size='340' side='right'caption='[[8cau]], [[Resolution|resolution]] 3.40Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[8cau]] is a 10 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Vicugna_pacos Vicugna pacos]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8CAU OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8CAU FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution|Resolution]] 3.4Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=NCT:(S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE'>NCT</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8cau FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8cau OCA], [https://pdbe.org/8cau PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8cau RCSB], [https://www.ebi.ac.uk/pdbsum/8cau PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8cau ProSAT]</span></td></tr> | |||
</table> | |||
== Disease == | |||
[https://www.uniprot.org/uniprot/ACHA7_HUMAN ACHA7_HUMAN] 15q13.3 microdeletion syndrome. | |||
== Function == | |||
[https://www.uniprot.org/uniprot/ACHA7_HUMAN ACHA7_HUMAN] After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin. | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
The human alpha7 nicotinic receptor is a pentameric channel mediating cellular and neuronal communication. It has attracted considerable interest in designing ligands for the treatment of neurological and psychiatric disorders. To develop a novel class of alpha7 ligands, we recently generated two nanobodies named E3 and C4, acting as positive allosteric modulator and silent allosteric ligand, respectively. Here, we solved the cryo-electron microscopy structures of the nanobody-receptor complexes. E3 and C4 bind to a common epitope involving two subunits at the apex of the receptor. They form by themselves a symmetric pentameric assembly that extends the extracellular domain. Unlike C4, the binding of E3 drives an agonist-bound conformation of the extracellular domain in the absence of an orthosteric agonist, and mutational analysis shows a key contribution of an N-linked sugar moiety in mediating E3 potentiation. The nanobody E3, by remotely controlling the global allosteric conformation of the receptor, implements an original mechanism of regulation that opens new avenues for drug design. | |||
An original potentiating mechanism revealed by the cryo-EM structures of the human alpha7 nicotinic receptor in complex with nanobodies.,Prevost MS, Barilone N, Dejean de la Batie G, Pons S, Ayme G, England P, Gielen M, Bontems F, Pehau-Arnaudet G, Maskos U, Lafaye P, Corringer PJ Nat Commun. 2023 Sep 25;14(1):5964. doi: 10.1038/s41467-023-41734-4. PMID:37749098<ref>PMID:37749098</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
[[Category: | <div class="pdbe-citations 8cau" style="background-color:#fffaf0;"></div> | ||
[[Category: | == References == | ||
[[Category: Ayme | <references/> | ||
[[Category: | __TOC__ | ||
[[Category: | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: | [[Category: Large Structures]] | ||
[[Category: | [[Category: Vicugna pacos]] | ||
[[Category: | [[Category: Ayme G]] | ||
[[Category: | [[Category: Barilone N]] | ||
[[Category: | [[Category: Bontems F]] | ||
[[Category: | [[Category: Corringer P-J]] | ||
[[Category: Dejean de la Batie G]] | |||
[[Category: England P]] | |||
[[Category: Gielen M]] | |||
[[Category: Lafaye P]] | |||
[[Category: Maskos U]] | |||
[[Category: Pehau-Arnaudet G]] | |||
[[Category: Pons S]] | |||
[[Category: Prevost MS]] | |||
Latest revision as of 08:55, 11 October 2023
human alpha7 nicotinic receptor in complex with the C4 nanobody and nicotinehuman alpha7 nicotinic receptor in complex with the C4 nanobody and nicotine
Structural highlights
DiseaseACHA7_HUMAN 15q13.3 microdeletion syndrome. FunctionACHA7_HUMAN After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin. Publication Abstract from PubMedThe human alpha7 nicotinic receptor is a pentameric channel mediating cellular and neuronal communication. It has attracted considerable interest in designing ligands for the treatment of neurological and psychiatric disorders. To develop a novel class of alpha7 ligands, we recently generated two nanobodies named E3 and C4, acting as positive allosteric modulator and silent allosteric ligand, respectively. Here, we solved the cryo-electron microscopy structures of the nanobody-receptor complexes. E3 and C4 bind to a common epitope involving two subunits at the apex of the receptor. They form by themselves a symmetric pentameric assembly that extends the extracellular domain. Unlike C4, the binding of E3 drives an agonist-bound conformation of the extracellular domain in the absence of an orthosteric agonist, and mutational analysis shows a key contribution of an N-linked sugar moiety in mediating E3 potentiation. The nanobody E3, by remotely controlling the global allosteric conformation of the receptor, implements an original mechanism of regulation that opens new avenues for drug design. An original potentiating mechanism revealed by the cryo-EM structures of the human alpha7 nicotinic receptor in complex with nanobodies.,Prevost MS, Barilone N, Dejean de la Batie G, Pons S, Ayme G, England P, Gielen M, Bontems F, Pehau-Arnaudet G, Maskos U, Lafaye P, Corringer PJ Nat Commun. 2023 Sep 25;14(1):5964. doi: 10.1038/s41467-023-41734-4. PMID:37749098[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||